Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Can we find a possible structural explanation for antibody-dependent enhancement of dengue virus infection resulting in hemorrhagic fever?

Mikita CP, Padlan EA.

Med Hypotheses. 2016 Mar;88:49-52. doi: 10.1016/j.mehy.2015.11.006. Epub 2015 Nov 14.

PMID:
26880637
2.

A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.

Nguyen AW, Wagner EK, Laber JR, Goodfield LL, Smallridge WE, Harvill ET, Papin JF, Wolf RF, Padlan EA, Bristol A, Kaleko M, Maynard JA.

Sci Transl Med. 2015 Dec 2;7(316):316ra195. doi: 10.1126/scitranslmed.aad0966.

3.

Can we use DNA triple helices as treatment for systemic lupus erythematosus?

Mikita CP, Padlan EA.

Med Hypotheses. 2014 Apr;82(4):457-9. doi: 10.1016/j.mehy.2014.01.024. Epub 2014 Jan 30.

PMID:
24513158
4.
5.

Analysis of the antibody structure based on high-resolution crystallographic studies.

Narciso JE, Uy ID, Cabang AB, Chavez JF, Pablo JL, Padilla-Concepcion GP, Padlan EA.

N Biotechnol. 2011 Sep;28(5):435-47. doi: 10.1016/j.nbt.2011.03.012. Epub 2011 Apr 6. Review.

PMID:
21477671
6.

BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.

Nishida M, Uematsu N, Kobayashi H, Matsunaga Y, Ishida S, Takata M, Niwa O, Padlan EA, Newman R.

Int J Oncol. 2011 Feb;38(2):335-44. doi: 10.3892/ijo.2010.864. Epub 2010 Dec 6.

PMID:
21152859
7.

Using simple artificial intelligence methods for predicting amyloidogenesis in antibodies.

David MP, Concepcion GP, Padlan EA.

BMC Bioinformatics. 2010 Feb 8;11:79. doi: 10.1186/1471-2105-11-79.

9.

Does the electrical activity of neurons contribute to the pathogenesis of Alzheimer's Disease?

Concepcion GP, Padlan EA.

Med Hypotheses. 2010 Jan;74(1):27-8. doi: 10.1016/j.mehy.2009.08.023. Epub 2009 Sep 3.

PMID:
19733011
10.

Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.

Nishida M, Teshigawara K, Niwa O, Usuda S, Nakamura T, Ralph P, Newman R, Padlan EA.

Int J Oncol. 2008 Jun;32(6):1263-74.

PMID:
18497988
11.

Why is there a greater incidence of allergy to the tropomyosin of certain animals than to that of others?

Mikita CP, Padlan EA.

Med Hypotheses. 2007;69(5):1070-3. Epub 2007 May 7.

PMID:
17482765
12.

A study of the structural correlates of affinity maturation: antibody affinity as a function of chemical interactions, structural plasticity and stability.

David MP, Asprer JJ, Ibana JS, Concepcion GP, Padlan EA.

Mol Immunol. 2007 Feb;44(6):1342-51. Epub 2006 Jul 18.

PMID:
16854467
14.

Water molecules in the antibody-antigen interface of the structure of the Fab HyHEL-5-lysozyme complex at 1.7 A resolution: comparison with results from isothermal titration calorimetry.

Cohen GH, Silverton EW, Padlan EA, Dyda F, Wibbenmeyer JA, Willson RC, Davies DR.

Acta Crystallogr D Biol Crystallogr. 2005 May;61(Pt 5):628-33. Epub 2005 Apr 20.

PMID:
15858274
15.
16.

SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV.

Mol Immunol. 2004 Jul;41(9):863-72.

PMID:
15261458
17.
18.

Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.

Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV.

Mol Immunol. 2003 Oct;40(6):337-49.

PMID:
14522015
19.

Are humans getting 'mad-cow disease' from eating beef, or something else?

Concepcion GP, Padlan EA.

Med Hypotheses. 2003 May;60(5):699-701.

PMID:
12710905
20.

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.

De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV.

J Immunol. 2002 Sep 15;169(6):3076-84.

21.

A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation.

Brams P, Black A, Padlan EA, Hariharan K, Leonard J, Chambers-Slater K, Noelle RJ, Newman R.

Int Immunopharmacol. 2001 Feb;1(2):277-94.

PMID:
11360929
22.

Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.

Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J.

Crit Rev Oncol Hematol. 2001 Apr;38(1):3-16. Review.

PMID:
11255077
24.
25.

CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.

Iwahashi M, Milenic DE, Padlan EA, Bei R, Schlom J, Kashmiri SV.

Mol Immunol. 1999 Oct-Nov;36(15-16):1079-91.

PMID:
10698310
26.

Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.

Santos AD, Kashmiri SV, Hand PH, Schlom J, Padlan EA.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3118s-3123s.

PMID:
10541352
27.

Structure-function studies of an anti-asialo GM1 antibody obtained from a phage display library.

Qiu JX, Kai M, Padlan EA, Marcus DM.

J Neuroimmunol. 1999 Jun 1;97(1-2):172-81.

PMID:
10408972
28.
29.

Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions.

Lee HS, Shu L, De Pascalis R, Giuliano M, Zhu M, Padlan EA, Hand PH, Schlom J, Hong HJ, Kashmiri SV.

Mol Immunol. 1999 Jan;36(1):61-71.

PMID:
10369421
30.

Protein and cell engineering of components of the human immunoglobulin E receptor/effector system: applications for therapy and diagnosis.

Helm BA, Sayers I, Swan J, Smyth LJ, Cain SA, Suter M, Machado DC, Spivey AC, Padlan EA.

Technol Health Care. 1998 Sep;6(2-3):195-207.

PMID:
9839864
31.

Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E.

Sayers I, Cain SA, Swan JR, Pickett MA, Watt PJ, Holgate ST, Padlan EA, Schuck P, Helm BA.

Biochemistry. 1998 Nov 17;37(46):16152-64.

PMID:
9819207
32.

Structure/function studies on IgE as a basis for the development of rational IgE antagonists.

Helm BA, Sayers I, Padlan EA, McKendrick JE, Spivey AC.

Allergy. 1998;53(45 Suppl):77-82. No abstract available.

PMID:
9788713
34.

Development of more efficacious antibodies for medical therapy and diagnosis.

Santos AD, Padlan EA.

Prog Nucleic Acid Res Mol Biol. 1998;60:169-94. Review.

PMID:
9594575
35.

Peptide blocking of IgE/receptor interaction: possibilities and pitfalls.

Helm BA, Spivey AC, Padlan EA.

Allergy. 1997 Dec;52(12):1155-69. Review. No abstract available.

PMID:
9450133
37.

Protein engineering from plants to animals, from big to small, from outside to inside and other advances.

Helm BA, Padlan EA.

Curr Opin Biotechnol. 1997 Aug;8(4):397-9. No abstract available.

PMID:
9265719
38.

A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties.

Reimann KA, Lin W, Bixler S, Browning B, Ehrenfels BN, Lucci J, Miatkowski K, Olson D, Parish TH, Rosa MD, Oleson FB, Hsu YM, Padlan EA, Letvin NL, Burkly LC.

AIDS Res Hum Retroviruses. 1997 Jul 20;13(11):933-43.

PMID:
9223409
39.

T-cell receptors: feeling out the complex.

Padlan EA, Marguilies DH.

Curr Biol. 1997 Jan 1;7(1):R17-20.

40.

A T cell receptor V alpha domain expressed in bacteria: does it dimerize in solution?

Plaksin D, Chacko S, McPhie P, Bax A, Padlan EA, Margulies DH.

J Exp Med. 1996 Oct 1;184(4):1251-8.

41.

Structural studies of human autoantibodies. Crystal structure of a thyroid peroxidase autoantibody Fab.

Chacko S, Padlan EA, Portolano S, McLachlan SM, Rapoport B.

J Biol Chem. 1996 May 24;271(21):12191-8.

42.

Identification of the high affinity receptor binding region in human immunoglobulin E.

Helm BA, Sayers I, Higginbottom A, Machado DC, Ling Y, Ahmad K, Padlan EA, Wilson AP.

J Biol Chem. 1996 Mar 29;271(13):7494-500.

43.

A humanized antibody with specificity for hepatitis B surface antigen.

Ryu CJ, Padlan EA, Jin BR, Yoo OJ, Hong HJ.

Hum Antibodies Hybridomas. 1996;7(3):113-22.

PMID:
9057059
44.

X-ray crystallography of antibodies.

Padlan EA.

Adv Protein Chem. 1996;49:57-133. Review. No abstract available.

PMID:
8908297
45.

Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.

Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH.

Hybridoma. 1995 Oct;14(5):461-73.

PMID:
8575795
46.

Identification of specificity-determining residues in antibodies.

Padlan EA, Abergel C, Tipper JP.

FASEB J. 1995 Jan;9(1):133-9.

PMID:
7821752
48.

Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.

Benhar I, Padlan EA, Jung SH, Lee B, Pastan I.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12051-5.

49.

Structure-function studies of anti-3-fucosyllactosamine (Le(x)) and galactosylgloboside antibodies.

Snyder JG, Dinh Q, Morrison SL, Padlan EA, Mitchell M, Yu-Lee LY, Marcus DM.

J Immunol. 1994 Aug 1;153(3):1161-70.

PMID:
7913110
50.

Humanization of KC4G3, an anti-human carcinoma antibody.

Couto JR, Padlan EA, Blank EW, Peterson JA, Ceriani RL.

Hybridoma. 1994 Jun;13(3):215-9.

PMID:
7927365

Supplemental Content

Loading ...
Support Center